Overview

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease (GERD).
Phase:
Phase 2
Details
Lead Sponsor:
Ironwood Pharmaceuticals, Inc.
Treatments:
Proton Pump Inhibitors